Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 3Phase NA 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3

Conditions

Neuroendocrine Tumors 3

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03724409 2023-11-28

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

University of Iowa

Phase EARLY_PHASE1 Terminated
3 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03044977 2023-08-16

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

University of Iowa

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03197012 2020-07-07

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

University of California, San Francisco

Phase EARLY_PHASE1 Completed
10 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡